

DAFTAR PUSTAKA

- Anwar A, Jafri F, Ashraf S, Jafri MAS, Fanucchi M. Paraneoplastic syndromes in lung cancer and their management. *Ann Transl Med.* 2019 Aug;7(15):359. doi: 10.21037/atm.2019.04.86. PMID: 31516905; PMCID: PMC6712246.
- Araghi M, Mannani R, Heidarnajad Maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F, Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Recent advances in non-small cell lung cancer targeted therapy; an update review. *Cancer Cell Int.* 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y. PMID: 37568193; PMCID: PMC10416536.
- Brambilla E, Travis WD. Lung cancer. In: *World Cancer Report*, Stewart BW, Wild CP (Eds), World Health Organization, Lyon 2014.
- Brzezniak C, Oronsky B, Carter CA, Thilagar B, Caroan S, Zeman K. Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report. *Case Rep Oncol.* 2017 Mar 17;10(1):252-257. doi: 10.1159/000464278. PMID: 28611639; PMCID: PMC5465747.
- Carter BW, Lichtenberger JP 3rd, Benveniste MK, de Groot PM, Wu CC, Erasmus JJ, Truong MT. Revisions to the TNM Staging of Lung Cancer: Rationale, Significance, and Clinical Application. *Radiographics.* 2018 Mar-Apr;38(2):374-391. doi: 10.1148/rg.2018170081. PMID: 29528831.
- Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General.* Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. 5, Cancer. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK53010/>
- Cho J, Choi SM, Lee J, Lee CH, Lee SM, Yim JJ, Chung DH, Yoo CG, Kim YW, Han SK, Park YS. The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas. *PLoS One.* 2016 Nov 18;11(11):e0166821. doi: 10.1371/journal.pone.0166821. PMID: 27861565; PMCID: PMC5115811.
- Ciofiac CM, Mămuleanu M, Florescu LM, Gheonea IA. CT Imaging Patterns in Major Histological Types of Lung Cancer. *Life.* 2024; 14(4):462. <https://doi.org/10.3390/life14040462>
- Cortot AB, Jänne PA. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. *Eur Respir Rev.* 2014 Sep;23(133):356-66. doi: 10.1183/09059180.00004614. PMID: 25176972; PMCID: PMC9487318.

- da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. *Annu Rev Pathol.* 2011;6:49-69. doi: 10.1146/annurev-pathol-011110-130206. PMID: 20887192.
- D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A, de Marinis F. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. *Ther Adv Med Oncol.* 2014 May;6(3):101-14. doi: 10.1177/1758834014521110. PMID: 24790650; PMCID: PMC3987652.
- De Guzman RB (2025) Early-onset lung cancer in Asia: a narrative review. *Front. Oncol.* 15:1631443. doi: 10.3389/fonc.2025.1631443
- Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. *Clin Chest Med.* 2011 Dec;32(4):605-44. doi: 10.1016/j.ccm.2011.09.001. PMID: 22054876; PMCID: PMC3864624.
- Dixit R, Agarwal KC, Gokhroo A, Patil CB, Meena M, Shah NS, Arora P. Diagnosis and management options in malignant pleural effusions. *Lung India.* 2017 Mar-Apr;34(2):160-166. doi: 10.4103/0970-2113.201305. PMID: 28360465; PMCID: PMC5351359.
- Du Y, Guo X, Wang R, Ma Y, Zhang Y, Liu Y, Dong L, Wu J, Ji X, Wang H. The Correlation between EGFR Mutation Status and DNA Content of Lung Adenocarcinoma Cells in Pleural Effusion. *J Cancer.* 2020 Feb 6;11(8):2265-2272. doi: 10.7150/jca.38615. PMID: 32127953; PMCID: PMC7052916.
- Du Y, Guo X, Wang R, Ma Y, Zhang Y, Liu Y, Dong L, Wu J, Ji X, Wang H. The Correlation between EGFR Mutation Status and DNA Content of Lung Adenocarcinoma Cells in Pleural Effusion. *J Cancer.* 2020 Feb 6;11(8):2265-2272. doi: 10.7150/jca.38615. PMID: 32127953; PMCID: PMC7052916.
- Erasmus LT, Strange TA, Agrawal R, Strange CD, Ahuja J, Shroff GS, Truong MT. Lung Cancer Staging: Imaging and Potential Pitfalls. *Diagnostics (Basel).* 2023 Nov 1;13(21):3359. doi: 10.3390/diagnostics13213359. PMID: 37958255; PMCID: PMC10649001.
- Felson, B., 2000. *Chest Roentgenology*. 3rd ed. Philadelphia: Saunders.
- Gaillard F, Yap J, Di Muzio B, et al. Large cell lung cancer. Reference article, Radiopaedia.org (Accessed on 17 Dec 2024) <https://doi.org/10.53347/rID-22405>
- Goto E, Taki T, Nomura K, Miyakami Y, Miyoshi T, Tane K, Samejima J, Aokage K, Nagamine M, Sakashita S, Sakamoto N, Kojima M, Suzuki K, Tsuboi M, Ishii G. Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern. *Lung Cancer.* 2024 Jun;192:107830. doi: 10.1016/j.lungcan.2024.107830. Epub 2024 May 23. PMID: 38805901.
- Guan J, Chen M, Xiao N, Li L, Zhang Y, Li Q, Yang M, Liu L, Chen L. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on

- PET/CT scan. *Med Oncol.* 2016 Jan;33(1):1. doi: 10.1007/s12032-015-0714-8. Epub 2015 Nov 20. PMID: 26589606.
- Han, X., Fan, J., Li, Y. *et al.* Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma. *Sci Rep* **11**, 5679 (2021). <https://doi.org/10.1038/s41598-021-83646-7>
- He J, Wang X, Xiao R, Zuo W, Zhang W, Yao H. Risk factors for brain metastases from non-small-cell lung cancer: A protocol for observational study. *Medicine (Baltimore)*. 2021 Mar 5;100(9):e24724. doi: 10.1097/MD.00000000000024724. PMID: 33655937; PMCID: PMC7939174.
- Herrera Ortiz AF, Garland ME, Almarie B. Clinical and Radiological Characteristics to Differentiate Between EGFR Exon 21 and Exon 19 Mutations in Patients With Lung Adenocarcinoma: A Systematic Literature Review and Meta-Analysis. *Cureus*. 2022 May 29;14(5):e25446. doi: 10.7759/cureus.25446. PMID: 35774697; PMCID: PMC9238903.
- Hmmier, Abduladim. (2018). Identification of Lung Carcinoma Biomarkers Associated with Tumour Development and Drug Resistance. 10.13140/RG.2.2.12606.92488.
- Iyer P, Ibrahim M, Siddiqui W, Dirweesh A. Syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) as an initial presenting sign of non small cell lung cancer-case report and literature review. *Respir Med Case Rep*. 2017 Aug 11;22:164-167. doi: 10.1016/j.rmcr.2017.08.004. PMID: 28856088; PMCID: PMC5565784.
- Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, Dias-Santagata D, Mathisen D, Lanuti M. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. *Ann Thorac Surg*. 2013 Sep;96(3):962-8. doi: 10.1016/j.athoracsur.2013.05.091. Epub 2013 Aug 8. PMID: 23932319.
- Kanaji N, Sakai K, Ueda Y, Miyawaki H, Ishii T, Watanabe N, Kita N, Kadota K, Kadowaki N, Bandoh S. Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease. *Lung Cancer*. 2017 Jun;108:126-133. doi: 10.1016/j.lungcan.2017.03.013. Epub 2017 Mar 27. PMID: 28625624.
- Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T. Paraneoplastic syndromes associated with lung cancer. *World J Clin Oncol*. 2014 Aug 10;5(3):197-223. doi: 10.5306/wjco.v5.i3.197. PMID: 25114839; PMCID: PMC4127595.
- Kato A, Hayashi M, Totii D, Sakakibara Y, Maeda S, Imaizumi K. Primary lung adenocarcinoma with gross calcification and suspected bone formation. *Fujita Med J*. 2020;6(3):87-90. doi: 10.20407/fmj.2019-019. Epub 2020 Feb 11. PMID: 35111527; PMCID: PMC8749503.

- Khan AN, Al-Jahdali HH, Allen CM, Irion KL, Al Ghanem S, Koteyar SS. The calcified lung nodule: What does it mean? *Ann Thorac Med*. 2010 Apr;5(2):67-79. doi: 10.4103/1817-1737.62469. PMID: 20582171; PMCID: PMC2883201.
- Le H, Wang X, Zha Y, Wang J, Zhu W, Ye Z, Liu X, Ma H, Zhang Y. Peripheral lung adenocarcinomas harboring epithelial growth factor receptor mutations with microRNA-135b overexpression are more likely to invade visceral pleura. *Oncol Lett*. 2017 Dec;14(6):7931-7940. doi: 10.3892/ol.2017.7195. Epub 2017 Oct 16. PMID: 29250182; PMCID: PMC5727608.
- Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, Zhang Z, Gao T, Zhang Y, Li L. Global burden and trends of lung cancer incidence and mortality. *Chin Med J (Engl)*. 2023 Jul 5;136(13):1583-1590. doi: 10.1097/CM9.0000000000002529. PMID: 37027426; PMCID: PMC10325747.
- Li L, Luo S, Lin H, Yang H, Chen H, Liao Z, Lin W, Zheng W, Xie X. Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer. *J Thorac Dis*. 2017 Aug;9(8):2510-2520. doi: 10.21037/jtd.2017.07.57. PMID: 28932557; PMCID: PMC5594201.
- Li Q, He XQ, Fan X, Luo TY, Huo JW, Huang XT. Computed Tomography Morphological Classification of Lung Adenocarcinoma and Its Correlation with Epidermal Growth Factor Receptor Mutation Status: A Report of 1075 Cases. *Int J Gen Med*. 2021 Jul 21;14:3687-3698. doi: 10.2147/IJGM.S316344. PMID: 34321914; PMCID: PMC8312332.
- Liu R, Zhou J, Ling X. Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With *EGFR* Mutation-Positive NSCLC. *Clin Med Insights Oncol*. 2022 Jun 24;16:11795549221103215. doi: 10.1177/11795549221103215. PMID: 35770234; PMCID: PMC9234848.
- Liu Y, Kim J, Qu F, Liu S, Wang H, Balagurunathan Y, Ye Z, Gillies RJ. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma. *Radiology*. 2016 Jul;280(1):271-80. doi: 10.1148/radiol.2016151455. Epub 2016 Mar 3. PMID: 26937803; PMCID: PMC4934516.
- Lu Q, Ma Y, An Z, Zhao T, Xu Z, Chen H. Epidermal growth factor receptor mutation accelerates radiographic progression in lung adenocarcinoma presented as a solitary ground-glass opacity. *J Thorac Dis*. 2018 Nov;10(11):6030-6039. doi: 10.21037/jtd.2018.10.19. PMID: 30622774; PMCID: PMC6297415.
- Mahoney MC, Shipley RT, Corcoran HL, Dickson BA. CT demonstration of calcification in carcinoma of the lung. *AJR Am J Roentgenol*. 1990 Feb;154(2):255-8. doi: 10.2214/ajr.154.2.2153329. PMID: 2153329.

- Makhdoomi R, Baba K, Malik R, Malik S, Rasool M, Mubeen B. Squamous cell carcinoma of lung with osteo-cartilaginous metaplasia - a case report and review of the literature. *Turk Patoloji Derg.* 2014;30(2):149-51. doi: 10.5146/tjpath.2013.01177. PMID: 24101350.
- Mets O., Smithuis R. Fleischner 2017 Guideline. 2024. <https://radiologyassistant.nl/chest/lung-anatomy/lung-segments>
- Mets O., Smithuis R. TNM classification 8th edition. 2017. <https://radiologyassistant.nl/chest/lung-cancer/tnm-classification-8th-edition>
- Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). *Am J Cancer Res.* 2015 Aug 15;5(9):2892-911. PMID: 26609494; PMCID: PMC4633915.
- Moon Y, Lee KY, Sung SW, Park JK. Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations. *J Thorac Dis.* 2016 Jan;8(1):169-77. doi: 10.3978/j.issn.2072-1439.2016.01.15. PMID: 26904226; PMCID: PMC4740167.
- Moore, K.L., Dalley, A.F. and Agur, A.M.R., 2013. *Clinically Oriented Anatomy*. 7th ed. Philadelphia: Lippincott Williams & Wilkins.
- Mourabiti, A.Y., Sqalli Houssaini, M., Benfares, A. *et al.* Clinical and radiological features associated with EGFR mutation in non-small-cell lung cancer: a study of 149 cases. *Egypt J Radiol Nucl Med* **54**, 171 (2023). <https://doi.org/10.1186/s43055-023-01122-w>
- Murphy C, Pandya T, Swanton C, Solomon BJ. Lung Cancer in Nonsmoking Individuals: A Review. *JAMA.* 2025 Nov 25;334(20):1836-1845. doi: 10.1001/jama.2025.17695. PMID: 41114991; PMCID: PMC7618360.
- Nagi NMS, Khair YAM, Bakari KH, Nagi MN, Mghanga FP. Tumor response to radiotherapy and expression of epidermal growth factor receptor mutation and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement in patients with non-small cell lung cancer. *J Egypt Natl Canc Inst.* 2022 Jul 11;34(1):29. doi: 10.1186/s43046-022-00130-7. PMID: 35811311.
- Nie Y, Gao W, Li N, Chen W, Wang H, Li C, Zhang H, Han P, Zhang Y, Lv X, Xu X, Liu H. Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma. *World J Surg Oncol.* 2017 Mar 3;15(1):55. doi: 10.1186/s12957-017-1103-x. PMID: 28253871; PMCID: PMC5335737.
- Panunzio A, Sartori P. Lung Cancer and Radiological Imaging. *Curr Radiopharm.* 2020;13(3):238-242. doi: 10.2174/1874471013666200523161849. PMID: 32445458; PMCID: PMC8206195.
- Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers"


- and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A*. 2004 Sep 7;101(36):13306-11. doi: 10.1073/pnas.0405220101. Epub 2004 Aug 25. PMID: 15329413; PMCID: PMC516528.
- Ren Y, Dai C, Zheng H, Zhou F, She Y, Jiang G, Fei K, Yang P, Xie D, Chen C. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. *Oncotarget*. 2016 Aug 16;7(33):53245-53253. doi: 10.18632/oncotarget.10644. PMID: 27449299; PMCID: PMC5288182.
- Rueschhoff AB, Moore AW, Jasahui MRP. Lung Cancer Staging—A Clinical Practice Review. *Journal of Respiration*. 2024; 4(1):50-61. <https://doi.org/10.3390/jor4010005>
- Sahn, S.A. and Heffner, J.E., 2000. "Pleural fluid analysis". *The New England Journal of Medicine*, 342(18), pp. 1360-1367.
- Saputra D. Asosiasi antara Ukuran Tumor Sumbu Terpanjang berdasarkan CT Scan Toraks dengan Status Mutasi *Epidermal Growth Factor Receptor* Positif dan Negatif pada Adenokarsinoma Paru. 2024. Program Pendidikan Dokter Spesialis I Radiologi Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan Universitas Gadjah Mada Yogyakarta.
- Saputra D. Hubungan antara Adenokarsinoma Paru Status Mutasi *Epidermal Growth Factor Receptor* Positif dan Negatif dengan Densitas Tumor berdasarkan CT Scan Toraks Non Kontras. 2024. Program Studi Magister Ilmu Kedokteran Klinis Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan Universitas Gadjah Mada Yogyakarta.
- Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. *Cancer Epidemiol Biomarkers Prev*. 2019 Oct;28(10):1563-1579. doi: 10.1158/1055-9965.EPI-19-0221. PMID: 31575553; PMCID: PMC6777859.
- Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. *Cancer Epidemiol Biomarkers Prev*. 2019 Oct;28(10):1563-1579. doi: 10.1158/1055-9965.EPI-19-0221. PMID: 31575553; PMCID: PMC6777859.
- Shi J, Yang Y, Zhao Y, Zhu J, Song X, Jiang G. *EGFR* mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients. *Cancer Manag Res*. 2019 Mar 1;11:1945-1957. doi: 10.2147/CMAR.S195747. PMID: 30881120; PMCID: PMC6402433.
- Shi J, Yang Y, Zhao Y, Zhu J, Song X, Jiang G. *EGFR* mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients. *Cancer Manag Res*. 2019 Mar 1;11:1945-1957. doi: 10.2147/CMAR.S195747. PMID: 30881120; PMCID: PMC6402433.
- Siddiqui F, Vaqar S, Siddiqui AH. Lung Cancer. [Updated 2023 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482357/>

- Siddiqui F, Vaqar S, Siddiqui AH. Lung Cancer. [Updated 2023 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482357/>
- Singh N, Madan K, Aggarwal AN, Das A. Symptomatic large bilateral adrenal metastases at presentation in small-cell lung cancer: a case report and review of the literature. *J Thorac Dis*. 2013 Jun;5(3):E83-6. doi: 10.3978/j.issn.2072-1439.2011.09.05. PMID: 23825789; PMCID: PMC3698258.
- Standring, S., 2016. *Gray's Anatomy: The Anatomical Basis of Clinical Practice*. 41st ed. Philadelphia: Elsevier.
- Sun F, Huang Y, Yang X, Zhan C, Xi J, Lin Z, Shi Y, Jiang W, Wang Q. Solid component ratio influences prognosis of GGO-featured IA stage invasive lung adenocarcinoma. *Cancer Imaging*. 2020 Dec 12;20(1):87. doi: 10.1186/s40644-020-00363-6. PMID: 33308323; PMCID: PMC7733294.
- Sun Q, Li P, Zhang J, Yip R, Yankelevitz DF, Henschke CI. CT Predictors of Angiolymphatic Invasion in Non-Small Cell Lung Cancer 30 mm or Smaller. *Radiology*. 2025 Jan;314(1):e240599. doi: 10.1148/radiol.240599. PMID: 39807982.
- Tanaka H, Karita M, Ueda K, Ono T, Kajima M, Manabe Y, Fujimoto K, Yuasa Y, Shiinoki T. Differences in Radiosensitivity According to EGFR Mutation Status in Non-Small Cell Lung Cancer: A Clinical and In Vitro Study. *J Pers Med*. 2023 Dec 25;14(1):25. doi: 10.3390/jpm14010025. PMID: 38248726; PMCID: PMC10820530.
- Tang X, Varella-Garcia M, Xavier AC, Massarelli E, Ozburn N, Moran C, Wistuba II. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. *Cancer Prev Res (Phila)*. 2008 Aug;1(3):192-200. doi: 10.1158/1940-6207.CAPR-08-0032. PMID: 19138956; PMCID: PMC3369271.
- Vakil J, Turk E, Cuartas-Mesa MC, Deenadayalan V, Batra K. Inpatient outcomes for lung cancer patients presenting with superior vena cava thrombosis. *Proc (Bayl Univ Med Cent)*. 2024 Mar 4;37(3):389-393. doi: 10.1080/08998280.2024.2317698. PMID: 38628350; PMCID: PMC11018079.
- Valvani A, Martin A, Devarajan A, Chandy D. Postobstructive pneumonia in lung cancer. *Ann Transl Med*. 2019 Aug;7(15):357. doi: 10.21037/atm.2019.05.26. PMID: 31516903; PMCID: PMC6712245.
- Wang A, Kubo J, Luo J, Desai M, Hedlin H, Henderson M, Chlebowski R, Tindle H, Chen C, Gomez S, Manson JE, Schwartz AG, Wactawski-Wende J, Cote M, Patel MI, Stefanick ML, Wakelee HA. Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort. *Ann Oncol*. 2015 Jan;26(1):221-230.

doi: 10.1093/annonc/mdu470. Epub 2014 Oct 14. PMID: 25316260; PMCID: PMC4326306.

- Wang, P., Sun, S., Lam, S. *et al.* New insights into the biology and development of lung cancer in never smokers—implications for early detection and treatment. *J Transl Med* **21**, 585 (2023). <https://doi.org/10.1186/s12967-023-04430-x>
- Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. *Cancers* (Basel). 2017 May 17;9(5):52. doi: 10.3390/cancers9050052. PMID: 28513565; PMCID: PMC5447962.
- Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung JY, Yen CJ, Shen CH, Kuo TY, Lee JY, Chou SH, Liu TC, Chong IW, Huang MS. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. *Lung Cancer*. 2015 May;88(2):187-94. doi: 10.1016/j.lungcan.2015.02.012. Epub 2015 Feb 23. PMID: 25747806.
- Xie X, Li X, Tang W, Xie P, Tan X. Primary tumor location in lung cancer: the evaluation and administration. *Chin Med J (Engl)*. 2021 Nov 15;135(2):127-136. doi: 10.1097/CM9.0000000000001802. PMID: 34784305; PMCID: PMC8769119.
- Yang L, Wang S, Gerber DE, Zhou Y, Xu F, Liu J, Liang H, Xiao G, Zhou Q, Gazdar A, Xie Y. Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma: A large cohort analysis. *Lung Cancer*. 2018 Jun;120:22-26. doi: 10.1016/j.lungcan.2018.03.011. Epub 2018 Mar 19. PMID: 29748011; PMCID: PMC7678407.
- Yang Q, Wang Z, Fu Q, Hu X, Chen L, Chen W, Lv L, Liu Z, Men W, Li D, Li W. *EGFR* mutations in patients with lung adenocarcinoma and malignant pleural effusion: a propensity score-matched analysis of a single-center database. *Transl Lung Cancer Res*. 2024 Sep 30;13(9):2435-2447. doi: 10.21037/tlcr-24-757. Epub 2024 Sep 27. PMID: 39430340; PMCID: PMC11484724.
- Zhang HY, Zhao J. Ectopic Cushing syndrome in small cell lung cancer: A case report and literature review. *Thorac Cancer*. 2017 Mar;8(2):114-117. doi: 10.1111/1759-7714.12403. Epub 2016 Nov 8. PMID: 28102935; PMCID: PMC5334324.
- Zhang, S., Xiao, X., Yi, Y. *et al.* Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. *Sig Transduct Target Ther* **9**, 149 (2024). <https://doi.org/10.1038/s41392-024-01848-7>
- Zhao Z, Gan H, Fu BJ, Li W, Lv F, Chu Z. A Comprehensive Study of Part-Solid Lung Adenocarcinoma with Lymph Node Metastasis: Clinical, Pathological, and Radiological Perspectives. *Cancer Manag Res*. 2025 May 26;17:1015-1027. doi: 10.2147/CMAR.S520781. PMID: 40454158; PMCID: PMC12125474.

Lampiran 1

 MEDICAL AND HEALTH RESEARCH ETHICS COMMITTEE (MHREC) FACULTY OF MEDICINE, PUBLIC HEALTH AND NURSING UNIVERSITAS GADJAH MADA – DR. SARDJITO GENERAL HOSPITAL 			
ETHICS COMMITTEE APPROVAL			
Ref. No. : KE/FK/0257/EC/2025			
Title of the Research Protocol	: Hubungan Antara Status Mutasi <i>Epidermal Growth Factor Receptors</i> (EGFR) dengan Karakteristik Massa, Pola Invasi, dan Lokasi Adenokarsinoma Paru pada Pemeriksaan Ct scan Thorax dengan Kontras		
Document(s) Approved and version	: Study Protocol version 01 2025		
Principle Investigator	: Karimah Amalia		
Participating Investigator(s)	: 1. Prof. Dr. dr. Lina Choridah, Sp.Rad(K)-PRP. 2. dr. Bambang P. Utomo, Sp.Rad(K)-Abd., M.Med.Ed.		
Date of Approval	: 21 FEB 2025 (Valid for one year beginning from the date of approval)		
Institution(s)/place(s) of research	: Instalasi Radiologi RSUP Dr. Sardjito Yogyakarta		
The Medical and Health Research Ethics Committee (MHREC) states that the document above meets the ethical principle outlined in the International and National Guidelines on ethical standards and procedures for researches with human beings.			
The Medical and Health Research Ethics Committee (MHREC) has the right to monitor the research activities at any time.			
The investigator(s) is/are obliged to submit: ☒ Progress report as a continuing review (state its due time) ☒ Report of any serious adverse events (SAE) ☒ Final report upon the completion of the study			
 Prof. dr. Tri Wibawa, Ph.D., Sp.MK(K). Panel's chairperson	 dr. Endy Paryanto, MPH., Sp.A(K). Panel's secretary		
P.S: This letter uses signature scan of the panel's chairperson and Secretary of the Ethics Committee. The hardcopy official letter with authority's signature will be issued when it is possible and are kept as an archive of the Ethics Committee <table border="1"><tr><td>Validation number : 67b7eddb926ab (http://komisietik.fk.ugm.ac.id/validasi)</td><td></td></tr></table>		Validation number : 67b7eddb926ab (http://komisietik.fk.ugm.ac.id/validasi)	
Validation number : 67b7eddb926ab (http://komisietik.fk.ugm.ac.id/validasi)			
Recognized by Forum for Ethical Review Committees in Asia and the Western Pacific (FERCAP) 20-Feb-25			

Lampiran 2



Nomor : DP.04.03/D.XI.2/3730/2025
Lampiran : Dua Lembar
Hal : Ijin Penelitian an. dr. Karimah Amalia

10 Februari 2025

Yth. Ketua Departemen Radiologi Fakultas Kedokteran, Kesehatan Masyarakat, Dan Keperawatan Universitas Gadjah Mada

Menjawab surat saudara, perihal tersebut pada pokok surat, pada prinsipnya kami dapat membantu dan mengijinkan pelaksanaan penelitian atas nama :

Nama : dr. Karimah Amalia
NIM : 22/507175/PKU/20738
Judul : *"Hubungan antara Status Mutasi Epidermal Growth Factor Receptors (EGFR) dengan Karakteristik Massa, Pola Invasi, dan Lokasi Adenokarsinoma Paru pada Pemeriksaan CT Scan Toraks dengan Kontras"*

Tempat Penelitian : Instalasi Radiologi Rumah Sakit RSUP Dr. Sardjito
dengan Ketentuan sebagai berikut :

1. Mematuhi protokol kesehatan di RSUP Dr. Sardjito
2. Sesuai prosedur tetap administrasi penelitian di RSUP Dr. Sardjito
3. Melengkapi *Ethics Commite Approval* dari Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan Universitas Gadjah Mada
4. Mencantumkan nama RSUP Dr. Sardjito di dalam naskah hasil penelitian
5. Menyerahkan hasil penelitian kepada RSUP Dr. Sardjito (Bagian Pendidikan dan Penelitian berupa CD, Instalasi Perpustakaan dan Instalasi terkait.

Untuk kelancaran penelitian tersebut agar menghubungi Bagian Pendidikan & Penelitian RSUP Dr. Sardjito, di pesawat (0274) 518669 pada hari dan jam kerja.

Atas perhatian dan kerja sama yang baik diucapkan terima kasih.

Direktur Sumber Daya Manusia,
Pendidikan, dan Penelitian,



drg. Nusati Ikawahju, M.Kes

Kementerian Kesehatan tidak menerima suap dan/atau gratifikasi dalam bentuk apapun. Jika terdapat potensi suap atau gratifikasi silakan laporkan melalui HALO KEMENKES 1500567 dan <https://wbs.kemkes.go.id>. Untuk verifikasi keaslian tanda tangan elektronik, silakan unggah dokumen

